A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to see if the combination pill E/C/F/TAF is safe and effective in reducing levels of HIV-1 in the blood of subjects who have kidney function problems.
Description
The purpose of this study is to see if the combination pill E/C/F/TAF is safe and effective in reducing levels of HIV-1 in the blood of subjects who have kidney function problems.
Details
| Condition | HIV |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX3481 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.